Articles / Value of pre-implantation genetic testing questioned
writer
Senior Research Fellow, Global and Women’s Health, School of Public Health & Preventive Medicine, Monash University
writer
Lorenzo and Pamela Galli Chair in Developmental Medicine, Murdoch Children’s Research Institute
If you’re going through IVF, you may be offered a test to look at your embryos’ chromosomes.
Pre-implantation genetic testing for aneuploidy (chromosome abnormalities), known as PGT-A, is an “add on” used to help choose embryos with the right number of chromosomes. It’s promoted by IVF clinics as a way to increase the chance of success, especially for women over 35.
But the evidence shows that in most cases, PGT-A doesn’t improve the chance of a baby.
Human cells usually contain 46 chromosomes. Aneuploidy is a term that describes a chromosome number that is different from 46 – either too many or too few chromosomes.
In human embryos, most aneuploidies are lethal, resulting in miscarriage, or do not result in pregnancy at all.
The chance of aneuploidy increases with the age of the woman; by the time a woman reaches age 40, approximately 80% of her embryos are aneuploid.
Heart Failure – Demystifying Pharmacological Management for GPs
Iron Deficiency in Children & Young People
Heart Failure – Assessment and Monitoring in Primary Care
COPD Update
writer
Senior Research Fellow, Global and Women’s Health, School of Public Health & Preventive Medicine, Monash University
writer
Lorenzo and Pamela Galli Chair in Developmental Medicine, Murdoch Children’s Research Institute
Strongly support
Somewhat support
Neither support nor oppose
Somewhat oppose
Strongly oppose
Listen to expert interviews.
Click to open in a new tab
Browse the latest articles from Healthed.
You have completed the Educational Activities component of this resource.
Select ‘Confirm & claim CPD‘ to confirm you have engaged with this resource in its entirety and claim your CPD.
You will be taken to explore further CPD learning available to you.